SCHEMBL30836715

SCHEMBL30836715

COC(OC)c1ccc(C(=O)Nc2cccc(B3OC(C)(C)C(C)(C)O3)c2Cl)nc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 9/20 0.50
▸ MEN1 O00255 1/20 0.37
▸ AHR P35869 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PDCD1 Q15116 2/20 0.34
▸ CD274 Q9NZQ7 2/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ P4HTM Q9NXG6 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PTPN11 Q06124 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CXCR2 P25025 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20293126 1.00 LIPE (0.50) LIPEMEN1AHRKMT2APDCD1
SCHEMBL20293697 0.90 LIPE (0.50) LIPEMEN1AHRKMT2APDCD1
SCHEMBL30836614 0.90 LIPE (0.50) LIPEMEN1AHRKMT2APDCD1
SCHEMBL20293076 0.89 LIPE (0.52) LIPEMEN1AHRKMT2ASMN1; SMN2
SCHEMBL21623038 0.85 LIPE (0.45) LIPEMEN1AHRKMT2APDCD1
SCHEMBL28793298 0.84 LIPE (0.52) LIPEMEN1AHRKMT2ACD274
SCHEMBL30836779 0.81 LIPE (0.50) LIPEMEN1AHRKMT2APDCD1
SCHEMBL30740164 0.79 MEN1 (0.43) MEN1AHRKMT2APDCD1CD274
SCHEMBL20293708 0.79 MEN1 (0.43) MEN1AHRKMT2APDCD1CD274
SCHEMBL25891782 0.76 LIPE (0.46) LIPEPDCD1CD274SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694981-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS Aurigene Oncology Limited (IN) 2026-02-18 — — EP disclosed
WO-2024214088-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS AURIGENE ONCOLOGY LIMITED (IN) 2024-10-17 — — WO disclosed
WO-2024069448-A1 SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-04-04 — — WO disclosed
Send feedback